AbbVie’s ABBV mid-stage studies of emraclidine for schizophrenia failed to meet their primary endpoint. Shares of the company ...

Leerink upgrades Bristol-Myers Squibb with an increased price target and strong sales projections for Cobenfy and milvexian, ...

In the company’s first insider transaction in nearly a year, Hirawat bought approximately $100,000 worth of BMY stock on Nov.

On Friday, Bristol-Myers Squibb Co (BMY) stock saw a decline, ending the day at $54.14 which represents a decrease of $-0.57 or -1.04% from the prior close of $54.71. The stock opened at $54.7 and ...

Bristol-Myers Squibb Co (NYSE:BMY) shares are trading higher Monday. The stock appears to be reacting positively after AbbVie ...

More than 40 groups have signed onto a letter asking Congress to end the prescription drug price control scheme included in the Inflation Reduction Act. President Biden is set to lay out his ...

On Tuesday, Bristol-Myers Squibb Co (BMY) stock saw a modest uptick, ending the day at $55.95 which represents a slight increase of $0.50 or 0.90% from the prior close of $55.45. The stock opened at ...

Morgan Stanley raised the firm’s price target on Bristol Myers (BMY) to $39 from $36 and keeps an Underweight rating on the shares ...

This is why empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements. Bristol Myers is expected to post earnings of $1.51 per ...

BMY) have crossed above the average analyst 12-month target price of $53.55, changing hands for $55.77/share. When a stock reaches the target an analyst has set, the analyst logically has two ways ...